Slide 1: Q3 2020 Earnings Conference Call
Q3 2020 Earnings Conference Call November 5, 2020 ©2020 ViewRay, Inc. All rights reserved. Exhibit 99.2
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “w
Slide 3: Our Mission: Treat and Prove What Others Can't
Our Mission: Treat and Prove What Others Can’t. More than installed systems globally1 disease sites treated1 11,000 40 >65 patients treated1 More than 2,800 patients with clinically reported outcomes1
Slide 4: Q3 2020 Financial Results Conference Call
Q3 2020 Financial Results Conference Call 4 MRIdian orders, including the VA Revenue: $10.1 million, including one revenue unit Used ~$16 million of cash Favorably amended SVB term loan
Slide 5: Where We Are Going
Where We Are Going Mission: Treat and Prove What Others Can’t Pancreas Beachhead Drive efficiency Expand proof in tough to treat and ubiquitous cancers Differentiated reimbursement
Slide 6: The Value of MRIdian
Mission: Treat and Prove What Others Can’t Deliver better outcomes in hard to treat and ubiquitous cancers Shrink treatment margins to spare healthy tissue Re-optimize radiation treatment plans to safely escalate dose Reduce fractionation (e.g. 40 to 5 or fewer) and accelerate ablative therapy adopt
Slide 7: Case courtesy of Dr. Chuong - Miami Baptist
Case courtesy of Dr. Chuong - Miami Baptist ©2020 ViewRay, Inc. All rights reserved. “ Oligomets in mesenteric lymph nodes Treat and Prove What Others Can’t Dr. Michael Chuong8 This case would never be treated on any other machine - period - to the dose we treated, period. ” ONLY on MRIdian
Slide 8: Expand utilization of MRIdian SMART: pancreas
Expand utilization of MRIdian SMART Become first line therapy In Practice: New Medicine in Pancreas Then – X-ray Guided NOW – MRIdian SMART 1-year survival: 59%1 1-year local control: 78%5 2-year survival: ~18%5 1-year survival: 87.5% - Cornell6 1-year local control: 91.8% - Moffitt7 87.8% - MCI8 2-
Slide 9: ASTRO 2020 Data Expanding the Clinical Compendium
Prostate: Acibadem - low toxicity and no fiducials required10 Renal: AUMC - zero grade 3 toxicity and 91% survival at 1-year11 Oligomets: MCI - zero grade 3 toxicity12 ASTRO 2020 Data Expanding the Clinical Compendium
Slide 10: Leap from x-ray guided linac to MRIdian SMART
Leap from x-ray guided linac to MRIdian SMART Great clinical results yet recognized disease may occur outside of target volumes Confidence in ability to protect healthy tissue and organs at risk led to re-thinking treatment of the disease vs. just the tumor8 Evolving to include the visible tumor and
Slide 11: MRIdian: See, Shape, Strike
` X-Ray based SBRT Extended Volume SMART Dose overlaps OAR oART: OAR are protected Prescribed radiation dose Implanted fiducials MRIdian: See, Shape, Strike Customer experience à confidence à re-thinking patient care Lymph node Tumor Blood vessel
Slide 12: The Value of MRIdian
Mission: Treat and Prove What Others Can’t Deliver better outcomes in hard to treat and ubiquitous cancers Shrink treatment margins to spare healthy tissue Re-optimize radiation treatment plans to safely escalate dose Reduce fractionation (e.g. 40 to 5 or fewer) and accelerate ablative therapy adopt
Slide 13: MRIdian helps customers achieve their macro goals
MRIdian helps customers achieve their macro goals Program Differentiation: Treat: Patients who were not candidates for radiation prior to MRIdian Attract: Patients traveling from outside catchment area Our Customers Macro Goals: Treat: Patients with the best possible care Attract: New patients into
Slide 14: The Future Is Now
The Future Is Now WE ARE DOING IT TODAY: MRIdian smart Cardiac sarcoma Locally advanced inoperable pancreatic cancer high dose Multiple pancreatic tumors high dose Reirradiation of ultra-central lung Reirradiation of central lung Ultra-central lung high dose Multiple liver mets high dose Rectal canc
Slide 15: Attract and Retain: MRIdian as a magnet
Attract and Retain MRIdian as a magnet Brigham and Women’s: 41 net new patients in the first year4 and record financial performance despite COVID-1917 GenesisCare Oxford, Dr. Das: “Most of my patients travel 120-130 miles. If you can provide the best treatment option, the patient will be willing to
Slide 16: New MRIdian Patients Create Economic Value
New MRIdian Patients Create Economic Value Approximately $8.5 million more in estimated revenue over the life of the system Economic value augmented by retaining patients within network, appropriate adaptive reimbursement, and cancer program differentiation Several MRIdian customers have purchased m
Slide 17: Patient Benefit
Patient Benefit Non-invasive Fewer side effects Improved quality of life Shorter courses of treatment Less disruption to their lives More savings from less travel Less exposure in COVID-19 era ©2020 ViewRay, Inc. All rights reserved. Source: internal company records
Slide 18: Where We Are Going
Where We Are Going Mission: Treat and Prove What Others Can’t Pancreas Beachhead Drive efficiency Expand proof in tough to treat and ubiquitous cancers Differentiated reimbursement
Slide 19: Financial Results Q3 2020
Financial Results Q3 2020 ©2020 ViewRay, Inc. All rights reserved.
Slide 20: Q3 2020 Financial Results Conference Call
Q3 2020 Financial Results Conference Call 4 MRIdian orders, including the VA Revenue: $10.1 million, primarily from one revenue unit Used ~$16 million of cash Favorably amended SVB term loan
Slide 21: Q3 2020 Financial Results
Q3 2020 Financial Results ©2020 ViewRay, Inc. All rights reserved.
Slide 22: SVB Term Loan Amendment
SVB Term Loan Amendment ©2020 ViewRay, Inc. All rights reserved. $56 million loan was set to begin amortizing in December of 2020 Extended maturity and restarted the interest-only period ~$35 million in amortization payments deferred until November 2022 Favorable interest rate + covenant improvement
Slide 23: Question and Answer Session
Question and Answer Session ©2020 ViewRay, Inc. All rights reserved.
Slide 24: Presentation Citations
Presentation Citations 12020 Internal and historical company data 2 Stereotactic MR-guided Adaptive Radiation Therapy 3 Total addressable market 4 “Day One, All-Day Adaptive: Dana-Farber/Brigham and Women's Cancer Center Maximizes Clinical Value of MRIdian,” 7/23/20 5 Herman JM, Chang DT, Goodman KA